1. Generics Bulletin
  2. >>Products
  3. >>Generics

IHP Responds To Ukraine Crisis

Makes Initial Shipment Of Essential Health Packs With Project HOPE

 
• By Dave Wallace

UK-based charity International Health Partners says it has made initial shipments of essential health packs in Ukraine to local partner Project HOPE and is evaluating next steps amid logistical barriers and complexity.

Ukraine Russia Flags Cracked
IHP has responded to the Ukraine crisis with shipments of essential health packs • Source: Tuomas Lehtinen / Alamy Stock Photo

UK-based charity International Health Partners has taken action in Ukraine as conflict continues following Russia’s invasion of the country.

More from Generics

Meitheal Adds To US Liraglutide List As It Looks To Ease Shortage Concerns

 
• By Dean Rudge

Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.

Glenmark Dodges UK Dapagliflozin Injunction Ahead Of Patent Trial Decision

 
• By Dean Rudge

A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Another One Bites The Dust: FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

 
• By Urtė Fultinavičiūtė

The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?

More from Products

Meitheal Adds To US Liraglutide List As It Looks To Ease Shortage Concerns

 
• By Dean Rudge

Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.

Glenmark Dodges UK Dapagliflozin Injunction Ahead Of Patent Trial Decision

 
• By Dean Rudge

A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.

Teva Shares Encouraging Patient Survey Data For Long-Acting Olanzapine

 
• By Adam Zamecnik

Doubling down on previously shared data from the firm’s STELARIS trial, Teva has reported further findings from a survey featuring subjects and professionals involved in the Phase III study for its proposed long-acting olanzapine injectable.